Minims Cyclopentolate Hydrochloride Bausch & Lomb Uk (Cyclopentolate Hydrochloride Bp)

Cyclopentolate works by competitively blocking muscarinic acetylcholine receptors in the iris sphincter and ciliary body. This inhibition prevents parasympathetic stimulation, causing the iris sphincter to relax (leading to pupil dilation) and the ciliary muscle to become inactive (resulting in loss of accommodation). The combined action yields mydriasis and cycloplegia.

The dosing regimen for cyclopentolate eye drops is determined by the prescribing clinician based on the specific indication, patient age, and ocular condition. Typically, one or two drops are instilled in the affected eye(s) and may be repeated after a short interval if greater dilation is required. Exact dosing instructions should always follow the prescriber’s order.

Cyclopentolate’s pregnancy category is listed as unknown, and there is limited data on its use during lactation. Because systemic absorption can occur, it should be used only if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate the risk‑benefit profile before prescribing to pregnant or nursing women.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Cyclopentolate provides both mydriasis and cycloplegia, whereas agents such as tropicamide mainly cause dilation with minimal cycloplegic effect. Cyclopentolate has a longer onset (5‑15 minutes) and duration (up to 24 hours) compared with tropicamide, which acts faster but wears off within a few hours. Choice of agent depends on the clinical need for accommodation paralysis and the desired duration of effect.

The eye‑drop solution should be stored at room temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from direct sunlight and moisture, and ensure the cap is tightly closed when not in use. Do not freeze the product, and discard any solution that appears discolored or contaminated.

The product is applied topically to the conjunctival sac. After washing hands, tilt the head back, gently pull down the lower eyelid, and instill the prescribed number of drops into the affected eye(s). Avoid touching the dropper tip to the eye or any surface to maintain sterility. Follow the prescriber’s instructions regarding repeat dosing.

The most serious risks include acute angle‑closure glaucoma in patients with narrow‑angle anatomy, systemic anticholinergic toxicity (manifesting as confusion, dry mouth, tachycardia, or urinary retention), and severe allergic reactions such as swelling or rash around the eye. Immediate medical attention is required if any of these serious symptoms develop.

Cyclopentolate should be avoided in individuals with known narrow‑angle or acute angle‑closure glaucoma, hypersensitivity to cyclopentolate or any component of the formulation, and in patients where significant systemic anticholinergic effects could be hazardous (e.g., severe cardiac disease, uncontrolled urinary retention). Clinicians should assess each patient’s ocular and systemic history before prescribing.